Learn More
PURPOSE Sunitinib has demonstrated antitumor activity in metastatic renal cell carcinoma (mRCC) when given at 50 mg/d on a 4-weeks-on 2-weeks-off regimen. Herein, we report results of an open-label,(More)
4527 Background: T administered at 3-week intervals is standard treatment for advanced HRPC. We compared 2-weekly to 3-weekly T as first-line chemotherapy of advanced HRPC (prior estramustine(More)